Paresh Soni, CEO
20+ years of executive pharmaceutical experience in Cardio-vascular diseases and NASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.
Damion J. Boyer, Co-Founder/COO
6 years experience as CEO of Corvidane. Responsible for initiating Corvidane’s NASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.
Bill Sasiela, VP of Translational Sci.
20+ years of pharmaceutical experience in roles that include Chief Medical Officer and SVP of Development with companies such as Esperion, Pfizer and Regeneron. Lead clinical/medical programs for a Statin (Lipitor), CETPs, MTPs, PCSK9s, ANGPTL3s and ACLs.
Patrice Binay, VP of Chemistry & CMC
32 years of pharmaceutical Fine Chemistry experience. Synthesis and analytical characterization of Active Pharmaceutical Ingredients, Quality auditing, Industrial Transfer. Development of a new class of anti-inflammatory (H4 Receptor).
Menno van Burken, VP of Commercial
32 years of global pharmaceutical experience across diverse commercial roles with Pfizer. Lead Cardiovascular and Metabolic therapeutic disease initiatives across R&D, Clinical Development, Medical Affairs, Regulatory and Commercial functions (inlcluding pricing market access, competitive intelligence)
John M. Burke, Co-Founder
Inventor of Corvida™ with 46 years Chemical Engineering expertise.